Skip to main content
Galmed Pharmaceuticals Ltd. logo

Galmed Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · GLMD ISIN · IL0011313900 LEI · 549300FL07PJ8ICSMD04 US Manufacturing
Open in API
Filings indexed 354 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country IL Israel
Listing US GLMD

About Galmed Pharmaceuticals Ltd.

https://www.galmedpharma.com

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company that develops therapeutics for liver, metabolic, and inflammatory diseases. The company's primary focus is on its lead product candidate, Aramchol, an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Aramchol is being evaluated in late-stage clinical trials, such as the ARMOR Phase 3 study, both as a monotherapy and in combination with other treatments. The company has also announced an expansion of its development activities to include cancer and other major cardiometabolic diseases.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 91% confidence The document is a SEC Form 6-K, which is a periodic report filed by a foreign private issuer under the Securities Exchange Act. It serves as a regulatory announcement of a press release and incorporation by reference. There is no dedicated category for Form 6-K in the taxonomy, so it falls under the general “Regulatory Filings” category (RNS).
2026-06-02 English
6-K
Regulatory Filings Classification · 92% confidence The document is a Form 6-K filed by a foreign private issuer reporting a press release under SEC Rule 13a-16 or 15d-16. It is a regulatory compliance filing (SEC Form 6-K) rather than a standalone annual report, earnings release, or other specific category. No specific category for Form 6-K exists, so it falls under the fallback “Regulatory Filings” (RNS).
2026-05-14 English
6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
Regulatory Filings
2026-05-06 English
6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galmed Pharmaceuticals Ltd. It reports a press release about a collaboration agreement. The document is short (1978 characters) and primarily serves to announce the press release, which is attached as Exhibit 99.1. There are no financial statements or detailed financial data included. The document is an announcement of information rather than a full report or detailed filing. According to the rules, such filings that do not fit other categories and serve as regulatory announcements fall under Regulatory Filings (RNS).
2026-04-14 English
6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It contains a press release about a product development but does not include detailed financial statements or comprehensive financial analysis. The document length is short (1580 characters), and it primarily serves as a regulatory announcement of a press release rather than a full report. According to the classification rules, such filings that do not fit into other specific categories and serve as regulatory announcements fall under Regulatory Filings (RNS).
2026-04-09 English
3 - Galmed Pharmaceuticals Ltd. (0001595353) (Issuer)
Director's Dealing
2026-03-18 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.